<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173819</url>
  </required_header>
  <id_info>
    <org_study_id>IAVI C100</org_study_id>
    <nct_id>NCT04173819</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults</brief_title>
  <official_title>Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2 study to evaluate the safety, tolerability, and pharmacokinetics of two
      broadly neutralizing monoclonal human antibodies (bNAbs), 3BNC117-LS-J, which targets the CD4
      binding site on HIV-1 envelope protein, and 10-1074-LS-J which targets the V3 loop of HIV-1
      envelope protein. The hypothesis is that the two antibodies will be safe for healthy HIV-1
      uninfected adults when co-administered subcutaneously or intravenously and, after
      subcutaneous administration in the optimal ratio, each antibody will maintain serum levels
      &gt;10 Âµg/ml for at least 3 months in HIV-uninfected participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is a randomized, double-blind, placebo-controlled Phase 1/2 study intended to evaluate the safety and pharmacokinetics of 10-1074-LS-J and 3BNC117-LS-J, alone or in combination, in healthy HIV-uninfected individuals.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Proportion of participants with solicited and treatment-related unsolicited adverse events and their duration.</measure>
    <time_frame>92 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with serious adverse events (SAEs) throughout the study period that are considered related to investigational product and their duration.</measure>
    <time_frame>92 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of each antibody in each group at multiple timepoints along with participant characteristics (e.g. sex, weight, and BMI)</measure>
    <time_frame>92 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The ratio of 3BNC117-LS-J to 10-1074-LS-J that, when injected SC, will maintain similar levels of each bNAb at steady state.</measure>
    <time_frame>92 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of anti-3BNC117-LS-J antibodies in each group at multiple timepoints.</measure>
    <time_frame>92 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of anti-10-1074-LS-J antibodies in each group at multiple timepoints.</measure>
    <time_frame>92 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Agent, abdominal subcutaneous injection, 10:2 ratio for Ab:placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single agent, abdominal subcutaneous injection 10:2 ratio for Ab:placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single agent intravenous injection 10:2 ratio for Ab:placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single agent intravenous injection 10:2 ratio for Ab:placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined agent intravenous injection 10:2 ratio for Ab:placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection combined ratio 1 with loading dose 30:3 ratio of Ab:Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection in abdomen combined ratio 2 with loading dose 30:3 ratio of Ab:Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection in abdomen combined ratio 3 with loading dose 30:3 ratio of Ab:Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection in abdomen combined ratio 2 without loading dose 30:3 ratio of Ab:Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection in arm combined ratio 2 without loading dose 30:3 ratio of Ab:Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3BNC117-LS-J</intervention_name>
    <description>300mg</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10-1074-LS-J</intervention_name>
    <description>300mg</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Combination 3BNC117-LS-J and 10-1074-LS-J</intervention_name>
    <description>30mg/kg of each</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1</intervention_name>
    <description>Total ~300 mg (&lt; 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2</description>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2</intervention_name>
    <description>Total ~300 mg (&lt; 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2</description>
    <arm_group_label>Group 10</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_label>Group 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3</intervention_name>
    <description>Total ~300 mg (&lt; 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2</description>
    <arm_group_label>Group 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Saline</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Buffer Solution</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 10</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_label>Group 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female individuals, as assessed by a medical history, physical exam,
             and laboratory tests

          -  At least 18 years of age on the day of screening and have not reached their 46th
             birthday on the day of the first administration

          -  Willing to undergo HIV testing, risk reduction counseling and receive HIV test
             results; committed to maintaining low-risk behavior for the trial duration

          -  Willing to comply with the requirements of the protocol and available for follow-up
             for the planned duration of the study

          -  All male and female participants of reproductive potential who are engaging in sexual
             activity that could lead to pregnancy must commit to use an effective method of
             contraception from enrollment until 9 months after the last administration

          -  Willing to forgo donations of blood, or any other tissues during the study following
             confirmation of study eligibility and, for those who test HIV-positive due to
             antibody-induced seropositivity, until the anti-HIV antibody titers become
             undetectable on HIV tests used in the community

        Exclusion Criteria:

          -  Confirmed HIV infection

          -  Reported risk for HIV infection within 6 months prior to investigational product
             administration, as defined by: Unprotected sexual intercourse with a known
             HIV-infected person, a partner known to be at high risk for HIV infection and/or a
             casual partner (i.e. no continuing established relationship), engaged in sex work,
             frequent excessive daily alcohol use or frequent binge drinking or any other use of
             illicit drugs, history of newly-acquired syphilis, gonorrhea, non-gonococcal
             urethritis, HSV-2, chlamydia, pelvic inflammatory disease (PID), trichomonas,
             mucopurulent cervicitis, epididymitis, proctitis, lymphogranuloma venereum, chancroid,
             or hepatitis B or hepatitis C, three or more sexual partners

          -  Any clinically significant acute or chronic medical condition that is considered
             progressive or in the opinion of the investigator makes the participant unsuitable for
             participation in the study

          -  Infectious disease diagnosis: Hepatitis B infection as measured by HbsAg and/or PCR,
             Hepatitis C infection (US: HCV RNA positive, or interferon-alpha treatment for
             hepatitis C infection in the past year, or interferon-alpha-free treatment for
             hepatitis C infection completed in the past 6 months; Africa: HCV Ab positive and/or
             PCR positive), active syphilis (positive RPR confirmed by TPHA)

          -  Receipt of blood transfusion or blood-derived products within the previous 3 months

          -  Participation in another clinical trial of an investigational product currently,
             within the previous 3 months or expected participation during this study (Concurrent
             participation in an observational trial not requiring blood or tissue sample
             collection is not an exclusion)

          -  Psychiatric condition that compromises safety of the participant and precludes
             compliance with the protocol. Specifically excluded are persons with psychoses within
             the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture
             within the past 3 years

          -  Body mass index (BMI) &gt;40

          -  Active tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Caskey, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dagna Laufer, MD</last_name>
    <phone>212-328-7459</phone>
    <email>Dlaufer@iavi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lindsey Baden, MD</last_name>
      <email>LBADEN@BWH.HARVARD.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Caskey, MD</last_name>
      <phone>212-327-7396</phone>
      <email>mcaskey@mail.rockefeller.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Louis</last_name>
      <phone>425-610-6448</phone>
      <email>info@seattlevaccines.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Partners in Health Research and Development</name>
      <address>
        <city>Thika</city>
        <state>Kiambu</state>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nelly Mugo, MMED</last_name>
      <email>nwamba@csrtkenya.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kenya AIDS Vaccine Initiative - Institute of Clinical Research</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaudensia Mutua, MD</last_name>
      <phone>+25472220417</phone>
      <email>gmutua@kaviunion.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Family Health Research</name>
      <address>
        <city>Kigali</city>
        <country>Rwanda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Etienne Karita, MD, MSc, MPH</last_name>
      <email>EKarita@rzhrg-mail.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wits Reproductive Health and HIV Institute</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sinead Delaney-Moretlwe, MD</last_name>
      <email>sdelaney@wrhi.ac.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uganda Virus Research Institute</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brenda Okech, PhD</last_name>
      <email>bokech@iavi.or.ug</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Institute Kasangati</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Mujugira, MD</last_name>
      <email>mujugira@uw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Rwanda</country>
    <country>South Africa</country>
    <country>Uganda</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://iavi.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

